These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33128367)

  • 1. A Cautionary Tale of Etanercept Use in Patients With Toxic Epidermal Necrolysis.
    Faris J; Wilson J; Dolman HS; Isaacson A; Baylor AE; Tyburski JG; White MT
    J Burn Care Res; 2021 May; 42(3):586-589. PubMed ID: 33128367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic epidermal necrolysis. A widespread, life-threatening blistering reaction.
    Watanakunakorn P; Brodell RT
    Postgrad Med; 2000 Apr; 107(4):29-30. PubMed ID: 10778408
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Pham CH; Gillenwater TJ; Nagengast E; McCullough MC; Peng DH; Garner WL
    Burns; 2019 Nov; 45(7):1634-1638. PubMed ID: 31466921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept.
    Gavigan GM; Kanigsberg ND; Ramien ML
    J Cutan Med Surg; 2018; 22(5):514-515. PubMed ID: 29421925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: A 25-year retrospective study at a single tertiary care center.
    Gleghorn KL; Voigt C; Kelly B
    Pediatr Dermatol; 2021 Jul; 38(4):812-818. PubMed ID: 34060145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic ocular complications in lamotrigine vs. trimethoprim-sulfamethoxazole induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Rashad R; Shanbhag SS; Kwan J; Chodosh J; Saeed S; Saeed HN
    Ocul Surf; 2021 Jul; 21():16-18. PubMed ID: 33932610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Wildermuth A
    JAAPA; 2020 Aug; 33(8):48-49. PubMed ID: 32740115
    [No Abstract]   [Full Text] [Related]  

  • 9. Stevens-Johnson syndrome and toxic epidermal necrolysis at the University Hospital of the West Indies, Jamaica.
    East-Innis AD; Thompson DS
    West Indian Med J; 2013 Sep; 62(7):589-92. PubMed ID: 24831894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous artifactual disease represented as recurrent toxic epidermal necrolysis.
    Gowring LE; Johnson R; Hivnor CM; Henning JS
    Cutis; 2016 Sep; 98(3):E6-E7. PubMed ID: 27814420
    [No Abstract]   [Full Text] [Related]  

  • 11. Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept.
    Estébanez A; Sáez-Martín LC; Muñoz JI; Silva E; Monrabal A; Monteagudo C; Ramón MD
    Pediatr Dermatol; 2020 Jul; 37(4):701-705. PubMed ID: 32319121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis.
    Woolridge KF; Boler PL; Lee BD
    Cutis; 2018 Jan; 101(1):E15-E21. PubMed ID: 29529123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimethoprim-sulfamethoxazole-induced Stevens-Johnson syndrome: a case report.
    Langlois MR; Derk F; Belczyk R; Zgonis T
    J Am Podiatr Med Assoc; 2010; 100(4):299-303. PubMed ID: 20660883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins.
    Paquet P; Jacob E; Damas P; Piérard GE
    Burns; 2001 Sep; 27(6):652-5. PubMed ID: 11525863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole.
    Rijal JP; Pompa T; Giri S; Bhatt VR
    BMJ Case Rep; 2014 Jul; 2014():. PubMed ID: 25008332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of toxic epidermal necrolysis.
    Craven NM
    Hosp Med; 2000 Nov; 61(11):778-81. PubMed ID: 11198746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
    Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
    Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cautionary Tale of Criteria Based on Anecdotal Evidence With Etanercept in Toxic Epidermal Necrolysis.
    LeWitt T; Claire SK; Daveluy S
    J Burn Care Res; 2021 Sep; 42(5):1059. PubMed ID: 33881535
    [No Abstract]   [Full Text] [Related]  

  • 20. Patch testing in an unusual case of toxic epidermal necrolysis.
    Klein CE; Trautmann A; Zillikens D; Bröcker EB
    Contact Dermatitis; 1996 Sep; 35(3):175-6. PubMed ID: 8930481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.